A Study of MHB048C in Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB048C monotherapy.

Trial Details

NCT ID
NCT07192120
Phase
PHASE1 / PHASE2
Sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • MHB048C for Injection
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntarily agrees to participate in the study and signs the informed consent form.
  • Age ≥ 18 years, no restriction on gender.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Estimated life expectancy ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →